{
  "citations": [
    {
      "id": 15079576,
      "title": "Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.",
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/24214521",
      "authors": [
        "Madadi Parvaz",
        "Amstutz Ursula",
        "Rieder Michael",
        "Ito Shinya",
        "Fung Vincent",
        "Hwang Soomi",
        "Turgeon Jacques",
        "Michaud Veronique",
        "Koren Gideon",
        "Carleton Bruce C",
        "CPNDS Clinical Recommendations Group"
      ],
      "crossReferences": [
        {
          "id": 1449281975,
          "resource": "PubMed",
          "resourceId": "24214521",
          "_url": "https://www.ncbi.nlm.nih.gov/pubmed/24214521",
          "version": 0
        }
      ],
      "hasKeyword": true,
      "journal": "Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique",
      "meshDiseases": [],
      "meshTerms": [
        "Analgesics, Opioid",
        "Codeine",
        "Cytochrome P-450 CYP2D6",
        "Decision Making",
        "Genetic Testing",
        "Genotype",
        "Humans",
        "Practice Guidelines as Topic"
      ],
      "month": 0,
      "nonHuman": false,
      "objCls": "Literature",
      "page": "e369-96",
      "pediatric": false,
      "pgkbPublication": false,
      "pubDate": "2012-12-01T00:00:00-08:00",
      "summary": "This guideline is intended to provide a basis for informed decision-making regarding genetic testing to identify those individuals who will not benefit from codeine therapy, as well as those who are at an increased risk for codeine-induced toxicity. This guideline addresses the following key questions: 1) Should genetic testing for CYP2D6 be performed in patients prior to the initiation of codeine therapy? 2) How should patients with an indication for codeine therapy be managed based on their genotyping results for CYP2D6?",
      "terms": [],
      "version": 2,
      "volume": "20",
      "year": 2013
    }
  ],
  "guideline": {
    "objCls": "Guideline Annotation",
    "id": "PA166122666",
    "name": "Annotation of CPNDS Guideline for codeine and CYP2D6",
    "alternateDrugAvailable": false,
    "cancerGenome": false,
    "crossReferences": [],
    "dosingInformation": false,
    "guidelineGenes": [],
    "hasTestingInfo": true,
    "history": [
      {
        "id": 1184511456,
        "date": "2014-07-28T00:00:00-07:00",
        "type": "Create",
        "version": 0
      },
      {
        "id": 1448616257,
        "date": "2017-05-02T11:11:47.674-07:00",
        "description": "added note about FDA safety announcment",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1451741761,
        "date": "2022-04-05T13:45:52.072-07:00",
        "description": "Added additional text from guideline publication and Testing Guidance tag",
        "type": "Update",
        "version": 0
      }
    ],
    "literature": [
      {"id":15079576,"title":"Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/24214521","crossReferences":[{"id":1449281975,"resource":"PubMed","resourceId":"24214521","_url":"https://www.ncbi.nlm.nih.gov/pubmed/24214521"}],"objCls":"Literature","terms":[]}
    ],
    "pediatric": false,
    "recommendation": true,
    "relatedAlleles": [],
    "relatedChemicals": [
      {
        "objCls": "Chemical",
        "id": "PA449088",
        "name": "codeine",
        "version": 12
      }
    ],
    "relatedGenes": [
      {
        "objCls": "Gene",
        "id": "PA128",
        "symbol": "CYP2D6",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "version": 7890
      }
    ],
    "source": "CPNDS",
    "summaryMarkdown": {
      "id": 1447982053,
      "html": "<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of <em>CYP2D6</em> genotype when prescribing codeine. They recommend that poor metabolizers of CYP2D6 should not receive codeine for pain relief, and ultrametabolizers of CYP2D6 should avoid codeine for pain relief.</p>\n",
      "version": 0
    },
    "terms": [],
    "textMarkdown": {
      "id": 1447982052,
      "html": "<p><em><strong>Note that the FDA released a <a rel=\"noopener noreferrer\" href=\"https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery\" target=\"_blank\">safety announcement</a> on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.</strong></em></p>\n<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published CYP2D6 genotype-based drug dosing guidelines for codeine in the <em>Journal of Population Therapeutics and Clinical Pharmacology</em>. Excerpts from &quot;Clinical Practice Guideline: <em>CYP2D6</em> genotyping for safe and efficacious codeine therapy&quot; [Article:<a href=\"/pmid/24214521\">24214521</a>] follow:</p>\n<blockquote class=\"blockquote\">\n<ul>\n<li>\n<p>Poor metabolizers of CYP2D6 should not receive codeine for pain relief (Grade A - strong recommendation).</p>\n</li>\n<li>\n<p>Ultrarapid metabolizers of CYP2D6 should avoid codeine for pain relief and receive alternative analgesics that do not have potent CYP2D6 metabolites (Grade B - moderate recommendation).</p>\n</li>\n<li>\n<p>Certain populations, especially opioid na√Øve breastfed neonates of mothers with functional CYP2D6 gene duplications taking codeine and young children may be particularly susceptible to codeine-induced central nervous system depression. Breastfeeding mothers and young children who are ultrarapid metabolizers of CYP2D6 should avoid codeine (Grade A - strong recommendation).</p>\n</li>\n<li>\n<p>In individuals with IM (intermediate metabolizer) or EM (extensive metabolizer) CYP2D6 genotypes, codeine can be used as per standard of care. Existing evidence suggests that caution is still warranted in CYP2D6 EMs receiving codeine if they are receiving maximal therapeutic doses of codeine and have additional risk factors for toxicity.</p>\n</li>\n</ul>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p><strong>Who should be tested and when?</strong></p>\n<ul>\n<li>Young children about to receive codeine for pain management and women about to receive codeine for postpartum pain while breastfeeding should be tested for CYP2D6 (Grade A - strong recommendation).</li>\n<li>Children and adults who continue to have pain despite high doses of codeine should be tested for CYP2D6 (Grade B - moderate recommendation).</li>\n<li>Genetic testing for CYP2D6 should be considered before administering codeine for the first time in all children and adults to rule out non-responders and to identify  individuals who may be susceptible to adverse effects from codeine(Grade C - optional recommendation).</li>\n</ul>\n</blockquote>\n<p>See full guideline ([Article:<a href=\"/pmid/24214521\">24214521</a>]) for further details and grading scheme.</p>\n",
      "version": 14
    },
    "userId": "carrillo",
    "version": 17
  }
}